---
document_datetime: 2024-03-08 16:17:07
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/emend-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: emend-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.7285182
conversion_datetime: 2025-12-19 05:00:18.045115
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## EMEND

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0069               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 06/03/2024                          |                                             | PL                               |           |
| N/0068               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 29/08/2022                          |                                             | PL                               |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0067/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/06/2022   | n/a   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0066/G   | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting | 20/10/2021   | n/a   |

<div style=\"page-break-after: always\"></div>

|         | material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates   |            |     |    | exist per material)   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|-----------------------|
| N/0065  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 07/09/2021 |     | PL |                       |
| N/0064  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/05/2021 |     | PL |                       |
| II/0063 | Update of the RMP to version 5.1 to remove all the safety concerns (important identified risks, important potential risks and missing information) and information related to both 40 mg and 165 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/10/2020 | n/a |    |                       |

<div style=\"page-break-after: always\"></div>

|                   | capsules strengths and the Postoperative Nausea and Vomiting indication (PONV), as well as to update data in the post-authorisation exposure (Part II: Module SV) and epidemiology (Part II: Module SI) sections - following the removal of 2 capsule strengths (40 mg and 165 mg) as well as the removal of the PONV indication as approved in variation IB/0062/G (EC adoption on 19 August 2020). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                                  |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0062/G         | This was an application for a group of variations. C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/06/2020 | 19/08/2020 | SmPC, Annex II, Labelling and PL |                                   |
| N/0061            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/11/2019 | 19/08/2020 | PL                               |                                   |
| PSUSA/229/2 01903 | Periodic Safety Update EU Single assessment - aprepitant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/10/2019 | n/a        |                                  | PRAC Recommendation - maintenance |
| IA/0060/G         | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/07/2019 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                   | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites   |            |            |                        |                                   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IAIN/0058         | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                       | 18/12/2018 | n/a        |                        |                                   |
| T/0057            | Transfer of Marketing Authorisation                                                                                                                                                                                                                       | 20/04/2018 | 24/05/2018 | SmPC, Labelling and PL |                                   |
| IA/0056           | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                       | 13/03/2018 | n/a        |                        |                                   |
| II/0055           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                         | 14/09/2017 | 19/10/2017 | SmPC, Labelling and PL |                                   |
| PSUSA/229/2 01603 | Periodic Safety Update EU Single assessment - aprepitant                                                                                                                                                                                                  | 27/10/2016 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0054   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                      | 15/09/2016   | n/a        |                                  |                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------|
| IA/0052   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/04/2016   | n/a        |                                  |                   |
| IB/0051/G | This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data) B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - marking | 23/03/2016   | 17/02/2017 | SmPC, Labelling and PL           | Device with CE    |
| X/0049/G  | This was an application for a group of variations. Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one in the SPC, Labelling or PL due to                                                                                                                                                                                                                                                                                | 22/10/2015   | 16/12/2015 | SmPC, Annex II, Labelling and PL | C.I.4 - Change(s) |

<div style=\"page-break-after: always\"></div>

|                   | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                     |            |            |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| PSUSA/229/2 01503 | Periodic Safety Update EU Single assessment - aprepitant                                                                                                                                                                                                                                                                         | 08/10/2015 | n/a        | PRAC Recommendation - maintenance |
| IA/0048/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                   | 08/12/2014 | n/a        |                                   |
| PSUV/0044         | Periodic Safety Update                                                                                                                                                                                                                                                                                                           | 09/10/2014 | n/a        | PRAC Recommendation - maintenance |
| N/0047            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                 | 16/09/2014 | 16/12/2015 |                                   |
| IB/0046           | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                           | 03/09/2014 | n/a        |                                   |
| IB/0045/G         | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for | 01/09/2014 | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

|           | the AS -replacement or addition of a site where batch control/testing takes place B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |            |                       |                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0042 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/10/2013 | 18/12/2013 | SmPC, Annex II and PL | Please refer to Emend-H-C-000527-PSUV-0042: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. In addition, the MAH took the opportunity to update the product information according to the latest QRD template. |
| IG/0366   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/11/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                 |
| N/0041    | Inclusion of an additional local representative of the MAH for Croatia. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/07/2013 | 18/12/2013 | PL                    |                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| WS/0354   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2 and 5.1 of the SmPC to reflect the recently approved safety dose restriction for ondansetron 32 mg IV. Additionally, the product information has been updated in accordance with the latest QRD template and the list of local representatives in the package leaflet was updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 21/02/2013   | 22/03/2013   | SmPC, Annex II and PL   | Based on the results from a recent clinical trial with ondansetron (5-HT3 receptor antagonist) and concerns about prolongation of the QT interval at a single IV dose of 32 mg section 5.1 of the SmPC has been updated to reflect that the ondansetron IV dose used concomitantly in clinical trials with aprepitant may no longer be the currently recommended dose. Furthermore references to the dose of ondansetron were removed from 4.2 referring the prescribing physician to the respective package insert for the selected co-administered 5-HT3 antagonist.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0038   | \"Alignment of the EMEND PI to the PI of IVEMEND R/018. This realignment includes updates of section 4.4, 4.5 and 4.6 of the SmPC and corresponding sections of the PL. The Applicant also updated the local representatives contact details in the PL for the following countries: Malta, The Netherlands, Poland, Iceland and Italy.\" C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                            | 13/12/2012   | 22/03/2013   | SmPC, Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IG/0182   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/08/2012   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0036/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/04/2012   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0035 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/02/2012 | 10/10/2012 | SmPC and PL | Alignment of the EMEND 165 mg PI to the PI of the other approved strengths of EMEND in line with the outcome of procedures II/029 and WS/180. This realignment includes the update of sections 4.8 and 6.5 of the SmPC and corresponding section of the PL. The MAH also updated the contact details in section 6 of the PL for EMEND 165 mg for the following countries: Greece, Hungary, Netherlands, Portugal, Latvia and Lithuania. |
| WS/0180 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC regarding \"toxic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/11/2011 | 19/12/2011 | SmPC and PL | Following the review of post-marketing safety reports of cases of Stevens-Johnson syndrome/toxic epidermal necrolysis, the work-sharing application proposed to update section 4.8 of the SmPC for Emend and Ivemend by adding                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | epidermal necrolysis\". The PIL is being updated accordingly. Furthermore, the MAH implemented the new QRD template v8 and a correction of a misleading reference is made in section 4.4 of the Ivemend SmPC. The list of local representatives is updated in section 6 of the PIL for both products. For Ivemend, Annex IIA is also being updated to align with information in Module 3. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |                                  | the term 'toxic epidermal necrolysis'.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0028  | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/09/2011 | 28/11/2011 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0029 | Alignment of Emend PI with Ivemend 115 mg and 150 mg PI agreed in previous procedures. Furthermore, section 4.8 of the SmPC is updated in line with the QRD template (7.3.1). The PIL is revised accordingly and the list of local representatives being updated. The DDPS and RMP information in Annex II is being modified. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                              | 22/09/2011 | 24/10/2011 | SmPC, Annex II and PL            | Fosaprepitant, the active ingredient in Ivemend, is a prodrug of aprepitant that is rapidly converted to aprepitant in vivo. As the pharmacologic activity of fosaprepitant is attributed to aprepitant, modifications introduced in the product information (PI) for Ivemend are also in many instances relevant for Emend. With the present variation, the MAH has aligned the PI for Emend with relevant modifications to the Ivemend PI recently approved in variation procedures II/009 and II/012, respectively. |
| IG/0112 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                                                                                                                                                                                                                                                                                         | 11/10/2011 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                         |            |     |           |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|-----------------------|
| N/0030    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                     | 06/07/2011 | n/a | PL        |                       |
| IA/0027   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                | 14/01/2011 | n/a |           |                       |
| IG/0027/G | This was an application for a group of variations. C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of system | 10/11/2010 | n/a | Annex II  | the pharmacovigilance |
| N/0025    | The MAH amended the immediate packaging (Annex IIIA) of the 2-day treatment pack. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                   | 19/08/2010 | n/a | Labelling |                       |
| IG/0008   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                              | 09/06/2010 | n/a |           |                       |

<div style=\"page-break-after: always\"></div>

| II/0024   | Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                               | 19/11/2009   | 12/01/2010   | SmPC, Labelling and PL   | Update of SPC sections 4.8 and 5.1 based on the safety and efficacy data from clinical study P130 (prevention of MEC-induced nausea and vomiting in a patient population with a variety of tumour types who were treated with a range of MEC agents). In SPC section 4.8 the number of patients in clinical trials and the combined data from studies P071 and P130 was updated for all strengths. The table presenting the adverse reactions observed in either highly emetogenic chemotherapy or moderately emetogenic chemotherapy studies in patients treated with the aprepitant regimen and at a greater incidence than with standard therapy was amended with the following adverse reactions with a frequency of \"uncommon\" under the respective System Organ Class: palpitation, somnolence and malaise, abdominal distension, faeces hard, neutropenic colitis, rash pruritic, muscular weakness, chills, gait disturbance, neutrophil count decreased and cardiovascular disorder. Furthermore, SPC section 5.1 for the 80mg and 125mg strengths was updated with efficacy data from clinical study P130. The package leaflet has been updated accordingly. In addition, section 4 of the package leaflet has been revised in order to improve the readability following a CHMP comment raised with a recently finalised variation procedure. Furthermore, the MAH took the opportunity to amend the labelling of the 125/80mg trifold pack as well as to insert the latest renewal date in the SPC.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023   | Update of the Detailed Description of the Pharmacovigilance System (DDPS). Annex II has been updated to reflect the version number of the | 25/06/2009   | 31/07/2009   | Annex II                 | The MAH updated its DDPS and submitted therefore this Type II variation. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | DDPS. In addition, in Annex II the version number of the RMP (version 2.1) has been updated following finalisation of the follow-up measure RMP028. Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             | the requirements and is considered acceptable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0022 | Update of SPC sections 4.4 and 4.5 regarding interaction with tolbutamide and oral contraceptives for the 40mg hard capsule based on two clinical pharmacology studies. In addition, SPC section 4.5 and PL section 2 have been revised as requested by CHMP with FUM026 of the EMEND renewal in order to simplify the text and increase readability. In this context, also in SPC section 4.4 an existing warning regarding concomitant orally administered active substances that are metabolised through CYP3A4 has been amended with a list of active substances with a narrow therapeutic range for the 80mg and 125mg strengths as well as the list of active substances that inhibit CYP3A4 activity for all strengths. Moreover, additional changes have been implemented in the Package Leaflet including an update to the list of local representatives. Update of Summary of Product Characteristics and Package Leaflet | 25/06/2009 | 31/07/2009 | SmPC and PL | SPC sections 4.4 and 4.5 have been updated based on two new interaction studies evaluating the effect of a 40mg single aprepitant oral dose. One study evaluated the effect over time on tolbutamide and one study the effect on an oral contraceptive. In the tolbutamide study the time course and magnitude of the induction, when assessed as the change over time from baseline, was similar as previously observed for the 3-day CINV regimen. However, the parallel placebo group also displayed a time dependent change. Hence, the overall placebo-corrected change was considerably smaller. However, given the unexpected results in the placebo group in the new study, it seems more appropriate to evaluate the inductive effect of Emend 40mg based on the change from baseline in the aprepitant group. Based on that, aprepitant 40mg single dose is a moderate inducer of CYP2C9 resulting in about 30% reduction in tolbutamide exposure. Also the oral contraceptive study suggests an inductive effect of a single 40mg aprepitant dose. The ethinyl estradiol AUC was decreased by 29% on Day 4 after aprepitant administration and trough concentrations were decreased up to 37%. This is less than the 64% decreased in ethinyl estradiol trough concentrations for the 3-day CINV regimen, but still suggest clinically relevant induction. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                   |            |            |                                  | In addition, for all strengths the statement regarding concomitant administration with active substances that inhibit CYP3A4 activity has been amended in SPC sections 4.4 and 4.5 with \"itraconazol, voriconazol, posaconazol, nefazodone\"; \"ritonavir\" was replaced by \"protease inhibitors\". Furthermore, for the 80 and 125mg strengths in SPC section 4.4 the existing warning regarding active substances concomitant orally administered active substances that are metabolised primarily through CYP3A4 has been amended. A list of CYP3A4 substrates with narrow therapeutic margin and where caution may be needed in case of a 2-3 fold increase in exposure over 3 days as could be expec   |
|---------|-----------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021 | IA_09_Deletion of manufacturing site                                              | 10/11/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0020  | Renewal of the marketing authorisation.                                           | 24/07/2008 | 22/09/2008 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Emend continues to be favourable. Adverse event of special interest will be further monitored by the MAH on a continuing basis. The CHMP is also of the opinion that the renewal can be                                                                                                                                                                            |
| IA/0019 | IA_05_Change in the name and/or address of a manufacturer of the finished product | 21/04/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IA/0018   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                    | 11/04/2008   | n/a        |                                  |                                                                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------|
| II/0017   | The variation concerns an update of the SPC on the concomitant use of EMEND and vinorelbine. Section 4.4 and 4.5 of the 80 and 125 mg SPC and section 6 of the PL have been updated. Update of Summary of Product Characteristics and Package Leaflet | 24/01/2007   | 28/02/2007 | SmPC, Annex II and PL            |                                                                        |
| IA/0016   | IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms                                                                                                                                                            | 01/08/2006   | n/a        |                                  |                                                                        |
| X/0015    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                            | 23/03/2006   | 29/05/2006 | SmPC, Annex II, Labelling and PL |                                                                        |
| II/0014   | Extension of Indication                                                                                                                                                                                                                               | 23/03/2006   | 29/05/2006 | SmPC, Annex II, Labelling and PL | Please refer to the Scientific Discussion document: Emend- H-527-II-14 |
| II/0011   | Update of Summary of Product Characteristics                                                                                                                                                                                                          | 15/09/2005   | 07/11/2005 | SmPC                             |                                                                        |
| II/0012   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                       | 15/09/2005   | 23/09/2005 |                                  |                                                                        |
| N/0013    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                      | 22/07/2005   | 07/11/2005 | PL                               |                                                                        |
| II/0010   | Update of the SPC section 4.5 to reflect the result of a clinical study showing that aprepitant had no                                                                                                                                                | 16/03/2005   | 28/04/2005 | SmPC                             |                                                                        |

<div style=\"page-break-after: always\"></div>

|         | significant effect on any of the pharmacokinetic parameters (AUC, maximum plasma concentration, time of maximum plasma concentration, half-life) of hydrodolasetron (the active metabolite of dolasetron). Update of Summary of Product Characteristics   |            |            |             |                                                                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------|
| II/0009 | Additional indication: \"Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy\". Extension of Indication                                                                                                             | 16/03/2005 | 28/04/2005 | SmPC and PL | Please refer to the Scientific Discussion document: Emend- H-527-II-09 |
| II/0006 | Update of the SPC sections 4.4 and 4.5 to add pharmacokinetic data regarding the interaction with oral contraceptives. Update of Summary of Product Characteristics and Package Leaflet                                                                   | 17/02/2005 | 30/03/2005 | SmPC and PL |                                                                        |
| IB/0008 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                | 27/10/2004 | n/a        | SmPC and PL |                                                                        |
| II/0005 | Update of the SPC section 4.5 on the concomitant use of EMEND and docetaxel. Update of Summary of Product Characteristics                                                                                                                                 | 16/09/2004 | 25/10/2004 | SmPC        |                                                                        |
| IB/0007 | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                                                                                                                                                      | 08/09/2004 | n/a        |             |                                                                        |

<div style=\"page-break-after: always\"></div>

| N/0004   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                       | 13/07/2004   | n/a   | Labelling and PL   |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------|
| N/0003   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                       | 14/06/2004   | n/a   | PL                 |
| IB/0002  | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                          | 14/04/2004   | n/a   |                    |
| IB/0001  | The MAH applied for the extension of shelf life of the finished product to 3 years. The MAH also took the opportunity to update the package leaflet for the telephone number of the German local representative and the full address of the Islandic local representatives. IB_42_a_01_Change in shelf-life of finished product - as packaged for sale | 14/04/2004   | n/a   | SmPC and PL        |